![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
Hepatitis Debrief
AASLD 2014
|
|
|
Michael W. Fried, M.D., FAASLD
Professor of Medicine
Director, UNC Liver Center
University of North Carolina at Chapel Hill
Reported by Jules Levin
AASLD Nov 7-11 Boston 2014
Hepatitis Debrief
AASLD 2014
Michael W. Fried, M.D., FAASLD
Professor of Medicine
Director, UNC Liver Center
University of North Carolina at Chapel Hill
Reported by Jules Levin
AASLD Nov 7-11 Boston 2014
![AASLD1.gif](../images/111214/111214-4/AASLD1.gif)
![AASLD2.gif](../images/111214/111214-4/AASLD2.gif)
![AASLD3.gif](../images/111214/111214-4/AASLD3.gif)
![AASLD4.gif](../images/111214/111214-4/AASLD4.gif)
![AASLD5.gif](../images/111214/111214-4/AASLD5.gif)
AASLD: Evaluation of sofosbuvir and simeprevir-based regimens in the TRIO network - Academic and community treatment of a real-world, heterogeneous population - (11/10/14)
![AASLD6.gif](../images/111214/111214-4/AASLD6.gif)
![AASLD7.gif](../images/111214/111214-4/AASLD7.gif)
![AASLD8.gif](../images/111214/111214-4/AASLD8.gif)
![AASLD9.gif](../images/111214/111214-4/AASLD9.gif)
![AASLD10.gif](../images/111214/111214-4/AASLD10.gif)
HCV TARGET - AASLD: Safety and Efficacy of Sofosbuvir-Containing Regimens for Hepatitis C: Real-World Experience in a Diverse, Longitudinal Observational Cohort - (11/10/14)
AASLD: Safety and Efficacy of New DAA---based Therapy for Hepatitis C Post---Transplant: Interval Results from the HCV---TARGET Longitudinal, Observational Study - (11/11/14)
![AASLD11.gif](../images/111214/111214-4/AASLD11.gif)
AASLD: An Integrated Safety and Efficacy Analysis of >500 Patients With Compensated Cirrhosis Treated With Ledipasvir/Sofosbuvir With or Without Ribavirin - (11/11/14)
![AASLD12.gif](../images/111214/111214-4/AASLD12.gif)
![AASLD13.gif](../images/111214/111214-4/AASLD13.gif)
![AASLD14.gif](../images/111214/111214-4/AASLD14.gif)
AASLD: Ledipasvir/Sofosbuvir Fixed-Dose Combination Is Safe and Efficacious in Cirrhotic Patients Who Have Previously Failed Protease-Inhibitor Based Triple Therapy ± - (11/11/14)
![AASLD15.gif](../images/111214/111214-4/AASLD15.gif)
![AASLD16.gif](../images/111214/111214-4/AASLD16.gif)
AASLD: INTEGRATED EFFICACY ANALYSIS OF FOUR PHASE 3 STUDIES IN HCV GENOTYPE 1A-INFECTED PATIENTS TREATED WITH ABT-450/R/OMBITASVIR AND DASABUVIR WITH OR WITHOUT RIBAVIRIN - (11/10/14)
![AASLD17.gif](../images/111214/111214-4/AASLD17.gif)
AASLD: All-Oral Fixed-Dose Combination Therapy With Daclatasvir/Asunaprevir/Beclabuvir, ±Ribavirin, for Patients With Chronic HCV Genotype 1 Infection and Compensated Cirrhosis: UNITY-2 Phase 3 SVR12 Results - (11/11/14)
![AASLD18.gif](../images/111214/111214-4/AASLD18.gif)
AASLD: All-Oral 12-Week Combination Treatment With Daclatasvir and Sofosbuvir in Patients Infected With HCV Genotype 3: ALLY-3 Phase 3 Study - (11/11/14)
![AASLD19.gif](../images/111214/111214-4/AASLD19.gif)
AASLD: Ledipasvir/Sofosbuvir With Ribavirin for the Treatment of HCV in Patients With Post- Transplant Recurrence: Preliminary Results of a Prospective, Multicenter Study - (11/11/14)
![AASLD20.gif](../images/111214/111214-4/AASLD20.gif)
AASLD: Use of Ledipasvir/Sofosbuvir Fixed Dose Combination for Treatment of HCV Genotype-1 Infection in Patients Coinfected with HIV - (11/10/14)
![AASLD21.gif](../images/111214/111214-4/AASLD21.gif)
![AASLD22.gif](../images/111214/111214-4/AASLD22.gif)
![AASLD23.gif](../images/111214/111214-4/AASLD23.gif)
![AASLD24.gif](../images/111214/111214-4/AASLD24.gif)
AASLD: C-SWIFT: Grazoprevir (MK-5172) + Elbasvir (MK-8742) + Sofosbuvir in Treatment-Naive Patients With Hepatitis C Virus Genotype 1 Infection, With and Without Cirrhosis, for Durations of 4, 6, or 8 Weeks (Interim Results) - (11/10/14)
![AASLD25.gif](../images/111214/111214-4/AASLD25.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|